한국어
Use this banner to inform your users of
something important.
2024년 11월 25일, Chosun
국내 5번째 디지털 치료제 '앵자이렉스', 범불안장애 치료 목표
HAII Corp.(대표 김진우)이 개발한 앵자이렉스는 임상시험을 마치고 식품의약품안전처에 허가를 신청,
디지털 헬스케어 혁신의 새로운 단계를 열었습니다.
자세히 보기
2024년 11월 04일, MoneyToday
수원과학대학교, 디지털 치료제 기반 정신 건강 지원 확대
HAII Corp.는 수원과학대학교 커뮤니티를 대상으로 ‘마음첵’과 ‘마음가든’ 서비스를 제공하며,
공동 연구 협력을 통해 디지털 헬스케어를 확대합니다.
2024년 10월 4일, ByLineNetwork
하이, 디지털 치료제 들고 한국 넘어 미국으로
AI 기반 진단 및 치료 솔루션을 개발 중인 HAII는 치매, 뇌졸중, 불안장애 등 다양한 영역에서 하버드 등 유수
기관과 협력하며 글로벌 임상 확대에 나섰습니다.
2024년 11월 2일, EToday
하이(HAII), 치매 예방 솔루션 ‘새미랑’ 조달청 혁신제품 선정
HAII의 인지 기능 평가 및 향상 서비스인 알츠가드-T가 조달청의 혁신 시제품으로 선정되어, 고령층의 치매
예방을 위한 뇌 검사 및 인지 훈련 도구로 활용됩니다.
AsiaTechDaily. (August 27, 2024)
HAII's 'Repeech' Gains US Approval for Key Clinical Trials
HAII Corporation has received US Institutional Review Board (IRB) approval from the Massachusetts General Hospital to initiate clinical trials for its digital speech rehabilitation therapeutic, “Repeech,” aimed at assisting stroke patients in
regaining speech capabilities.
KoreaTechDesk. (August 9, 2024)
HAII Secures Second Place in KHIDI-Roche Diagnostics Day's "New Impact Project"
HAII's strong performance in the competition highlights its potential for global expansion in the digital biomarker and AI healthcare sectors, positioning the company for significant international growth.
AITimes. (July 2, 2024)
HAII Highlights Role of Explainable AI in Digital Health at XAI Workshop 2024
At the ‘KCC XAI Workshop 2024,’ HAII presented its advancements in digital therapeutics, showcasing how explainable AI enhances patient trust and clinical outcomes, particularly through its speech therapy app, “Repeech,” which leverages XAI for improved transparency and personalized treatment.
HealthInNews. (June 18, 2024)
HAII Signs Comprehensive Partnership Agreement with IM Rehabilitation Hospital
HAII and IM Rehabilitation Hospital have entered into a collaboration to develop and commercialize the digital therapeutic "Repeech" for stroke-related speech and cognitive rehabilitation.
BioTimes (April 25, 2024)
HAII Secures MFDS Approval for Confirmatory Clinical Trials of Dementia Diagnostic Digital Device
HAII becomes the first in South Korea to receive MFDS approval for clinical trials of its diagnostic digital device, Alzguard, which uses digital biomarkers like voice, eye movement, and cognitive response for early detection.
ENewToday. (February 26, 2024)
HAII Receives Approval from the MFDS for Confirmatory Clinical Trials of ‘Repeech’
HAII has secured approval from South Korea’s Ministry of Food and Drug Safety (MFDS) to conduct confirmatory clinical trials for its digital speech therapy solution ‘Repeech,’ designed to aid post-stroke patients in speech rehabilitation through a mobile app.
Terms of Use I Privacy Policy
@Copyright 2022. All Right Reserved. Hosted by Imweb
Privacy Policy
@Copyright 2025. All Right Reserved.
